Gemcitabine News and Research

RSS

Gemcitabine is the active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used together with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite

Incyte announces results of Phase II clinical trial of oral JAK1 inhibitor in patients with RA

Incyte Corporation (Nasdaq: INCY) announced results from a 12-week, placebo-controlled, dose-escalationin involving 60 patients with active rheumatoid arthritis for its proprietary oral JAK1 inhibitor.

29 Oct 2013

Pancreatic cancer patients may benefit from antibody-drug conjugates

Patients with pancreatic cancer may benefit from an investigational member of an emerging class of anticancer drugs called antibody-drug conjugates, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

22 Oct 2013

Cell Therapeutics presents preclinical study results of PIXUVRI at AACR-NCI-EORTC meeting

Cell Therapeutics, Inc. (CTI) today announced the presentation of findings from a preclinical study of PIXUVRI® (pixantrone) that suggest its mechanism of inducing tumor cell death is novel and distinct from that of anthracyclines such as doxorubicin.

21 Oct 2013

Two drugs in combination improve survival in patients with advanced pancreatic cancer

Investigators at the Vall d´Hebron University Hospital and the Vall d'Hebron Institute of Oncology (VHIO), have participated in an international phase III study, published in The New England Journal of Medicine.

18 Oct 2013

NEJM publishes Celgene’s Abraxane phase III study results

Published today in the New England Journal of Medicine, a phase III clinical trial of Abraxane (paclitaxel formulated as albumin-bound nanoparticles) in combination with gemcitabine in treatment-naive patients with metastatic pancreatic cancer demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone [(median of 8.5 vs. 6.7 months) (HR 0.72, P=0.000015)].

17 Oct 2013

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation , today announced the results of the MPACT phase III clinical trial of ABRAXANE® in combination with gemcitabine were published online in the October 16th edition of the New England Journal of Medicine.

17 Oct 2013

NICE issues second draft guidance on PIXUVRI for treatment of aggressive B-cell NHL

Cell Therapeutics, Inc. today announced that the National Institute for Health and Care Excellence, a non-departmental public body of the Department of Health in the United Kingdom, issued second draft guidance on PIXUVRI (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.

15 Oct 2013

Gemcitabine drug improves survival rates in patients with pancreatic cancer

Among patients with pancreatic cancer who had surgery for removal of the cancer, treatment with the drug gemcitabine for 6 months resulted in increased overall survival as well as disease-free survival, compared with observation alone, according to a study in the October 9 issue of JAMA.

9 Oct 2013

Researchers identify potentially treatable subtype of pancreatic cancer

Australian researchers have identified a potentially treatable subtype of pancreatic cancer, which accounts for about 2% of new cases. This subtype expresses high levels of the HER2 gene. HER2-amplified breast and gastric cancers are currently treated with Herceptin.

17 Sep 2013

FDA approves ABRAXANE chemotherapy drug for treatment of metastatic pancreatic cancer

The Pancreatic Cancer Action Network is pleased to announce that today ABRAXANE® was approved by the U.S. Food and Drug Administration (FDA) to treat metastatic pancreatic cancer.

7 Sep 2013

FDA approves use of abraxane to treat patients with late-stage pancreatic cancer

The U.S. Food and Drug Administration today expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, ablumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer.

7 Sep 2013

Abraxane drug gets FDA approval for patients with advanced pancreatic cancer

The U.S. Food and Drug Administration today approved Abraxane for patients with advanced pancreatic cancer, following 7 years of rigorous clinical trials overseen by Scottsdale Healthcare and the Translational Genomics Research Institute.

7 Sep 2013

New delivery system for combination of 2 FDA approved drugs to fight HIV

A University of Minnesota research team featuring researchers from the Institute for Molecular Virology, School of Dentistry and Center for Drug Design has developed a new delivery system for a combination of two FDA approved drugs that may serve as an effective treatment for the human immunodeficiency virus (HIV).

31 Aug 2013

FDA grants Priority Review designation to sNDA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted Priority Review designation to the supplemental New Drug Application for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

27 Aug 2013

Flavonoids in celery, artichokes induce apoptosis in human pancreatic cancer cells

Celery, artichokes, and herbs, especially Mexican oregano, all contain apigenin and luteolin, flavonoids that kill human pancreatic cancer cells in the lab by inhibiting an important enzyme, according to two new University of Illinois studies.

16 Aug 2013

Phase III trial shows afatinib offers clinical benefit to patients with EGFR mutation positive NSCLC

Afatinib has a novel mode of action and data has shown that it offers a clinical benefit to patients with a specific type of lung cancer, which we are further investigating in the extensive LUX-Lung clinical trial programme.

1 Aug 2013

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Nektar Therapeutics (NASDAQ: NKTR) today announced that enrollment is complete in the pivotal clinical study of etirinotecan pegol (NKTR-102) in patients with metastatic breast cancer.

31 Jul 2013

Mylan Pharmaceuticals agrees to resolve patent litigation related to Erlotinib Hydrochloride Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a settlement agreement with OSI, Pfizer and Genentech that will resolve patent litigation related to Erlotinib Hydrochloride Tablets, 25 mg, 100 mg and 150 mg.

24 Jul 2013

OncoGenex completes enrollment in OGX-427 Phase 2 trial for treatment of metastatic bladder cancer

OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.

16 Jul 2013

AIFA grants market access for CTI's PIXUVRI to treat patients with aggressive B-cell NHL

Cell Therapeutics, Inc. today announced that the Company has been granted market access by the Italian Medicines Agency for the medicinal product PIXUVRI (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (patients with aggressive B-cell NHL who failed 2 or 3 prior lines of therapy).

8 Jul 2013

Gemcitabine News and Research

Incyte announces results of Phase II clinical trial of oral JAK1 inhibitor in patients with RA

Pancreatic cancer patients may benefit from antibody-drug conjugates

Cell Therapeutics presents preclinical study results of PIXUVRI at AACR-NCI-EORTC meeting

Two drugs in combination improve survival in patients with advanced pancreatic cancer

NEJM publishes Celgene’s Abraxane phase III study results

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

NICE issues second draft guidance on PIXUVRI for treatment of aggressive B-cell NHL

Gemcitabine drug improves survival rates in patients with pancreatic cancer

Researchers identify potentially treatable subtype of pancreatic cancer

FDA approves ABRAXANE chemotherapy drug for treatment of metastatic pancreatic cancer

FDA approves use of abraxane to treat patients with late-stage pancreatic cancer

Abraxane drug gets FDA approval for patients with advanced pancreatic cancer

New delivery system for combination of 2 FDA approved drugs to fight HIV

FDA grants Priority Review designation to sNDA for Nexavar tablets

Flavonoids in celery, artichokes induce apoptosis in human pancreatic cancer cells

Phase III trial shows afatinib offers clinical benefit to patients with EGFR mutation positive NSCLC

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Mylan Pharmaceuticals agrees to resolve patent litigation related to Erlotinib Hydrochloride Tablets

OncoGenex completes enrollment in OGX-427 Phase 2 trial for treatment of metastatic bladder cancer

AIFA grants market access for CTI's PIXUVRI to treat patients with aggressive B-cell NHL

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News